Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management
Sensor Augmented Pump (SAP) Therapy for Inpatient Cystic Fibrosis Related Diabetes (CFRD) Management
Sponsor: Cystic Fibrosis Foundation
Terminated
Decreased admissions secondary to wider introduction of HEMTs along with pandemic impacted ability to enroll
Other terminated trials from Cystic Fibrosis Foundation
Listed as NCT03939065, this NA trial focuses on Cystic Fibrosis Pulmonary Exacerbation and Cystic Fibrosis in Children and remains terminated or withdrawn. Sponsored by Cystic Fibrosis Foundation, it has been updated 12 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Apr 2023 — Jul 2024 [monthly]
Terminated NA
-
Dec 2022 — Apr 2023 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Sep 2021 — Dec 2022 [monthly]
Recruiting NA
▶ Show 7 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Recruiting NA
-
Dec 2020 — Jan 2021 [monthly]
Recruiting NA
-
Sep 2020 — Dec 2020 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Apr 2020 — Sep 2020 [monthly]
Not Yet Recruiting NA
-
Feb 2020 — Apr 2020 [monthly]
Not Yet Recruiting NA
-
Nov 2019 — Feb 2020 [monthly]
Not Yet Recruiting NA
-
Jun 2019 — Nov 2019 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cystic Fibrosis Foundation
- University of Colorado, Denver
For direct contact, visit the study record on ClinicalTrials.gov .